Celebrated this Sunday, January 30, the World Day for Neglected Tropical Diseases draws attention to infections that affect more than 1 billion people in the world, but receive little attention and investment. Affecting mainly poor people, diseases such as Chagas disease, dengue, leishmaniasis, leprosy, schistosomiasis and verminoses cause great damage to health, can lead to death and even worsen people's living conditions, as they make it difficult to stay in school and in the job market. work.
Among the many faces of negligence, which includes lack of access to available prevention, diagnosis and treatment measures, is the low investment in research and development of safe and effective therapies. It is in this context that the 'Selenium Project', led by the Oswaldo Cruz Institute (IOC/Fiocruz) in partnership with the Evandro Chagas National Institute of Infectology (INI/Fiocruz), celebrates another step in the search for a new therapy for heart problems caused by chronic Chagas disease.

Published in the international scientific journal 'EClinicalMedicine', the result of the first clinical trial with selenium supplementation for patients with Chagas heart disease pointed out a potential benefit of the treatment, in at least a subgroup of patients. The study included patients with chronic Chagas disease with mild to moderate heart problems, which are classified as stage B. The work confirmed the safety of using selenium, with no record of adverse reactions. In the subgroup of patients with moderate heart disease, classified as stage B2, the analyzes showed that the evolution of the severity of the problems improved after treatment.
According to the authors of the research, the result is positive and indicates that further studies should be carried out. “We generated the first evidence, obtained in a randomized clinical trial, on the benefit of selenium for patients in stage B2 of chronic heart disease in Chagas disease. It was a statistically significant result, but in a small sample. Now, confirmation in new research is important, including longer follow-up time, more patients in stage B2, patients in stage C and volunteers from different regions of Brazil”, says the project coordinator, researcher at the Laboratory of Innovations in Therapy, Education and Bioproducts and director of IOC, Tania Cremonini de Araujo-Jorge.
“This was the first randomized clinical trial that tested the use of selenium to prevent worsening of the contractile function of the heart in Chagas heart disease. The trial showed that there is a subgroup of patients in whom the treatment was beneficial, which encouraged us a lot and raised questions for further research”, adds the first author of the article, a cardiologist and researcher at the Laboratory of Clinical Research in Chagas Disease at the INI , Marcelo Holland.
Sixty-six patients treated at the INI's Chagas disease outpatient clinic participated in the survey. To assess the effect of therapy, volunteers were divided into two groups. One received daily supplementation with selenium capsules and the other, considered as a control, received identical capsules containing an inert compound, called a placebo. Each patient was followed up for one year, with clinical consultations, laboratory tests and heart tests.
The research followed protocols considered the gold standard for clinical trials. The volunteers were randomly allocated to the groups to receive the treatment or the placebo, through a procedure called randomization, which causes the two groups to have patients with similar profiles in terms of factors that may influence the outcome of the study, such as age, gender, severity of heart problems, and medications used for heart disease.
Furthermore, during the entire follow-up, both patients and raters were unaware of who was receiving selenium and who was taking a placebo. Called blinding, the procedure avoids the predisposition to recognize signs of improvement in those who used the medication or worsening in those who did not.
At the end of the study, the evolution of the disease in the two groups was compared. The most relevant result was observed among patients with stage B2 heart disease, who initially had a moderate loss of heart contraction strength. After a year of follow-up, the volunteers who took selenium maintained or improved their heart function, while those who took a placebo maintained the same condition or worsened. Considering the average of each group, the difference was statistically significant.
Among patients with stage B1 heart disease, who had mild changes in cardiac function at the beginning of the study, no statistically significant difference was observed between the treated group and the placebo group after one year of follow-up. However, some data indicate that there may be benefit from treatment, and that longer follow-up would be indicated, as some cases of improvement in heart function were observed only among patients who took selenium. In total participants, on average, disease progression was somewhat less pronounced among selenium-treated volunteers.

According to the authors of the study, a longer follow-up of the volunteers should contribute to elucidate the potential benefit of selenium. “Based on the results of the clinical trial, we can indicate that selenium replacement could be an adjuvant treatment to delay the progression of the disease. Now, it is necessary to increase the follow-up period from one to five years and verify whether this positive trend of less progress is maintained. If that happens, the next step is to incorporate selenium supplementation into the treatment routine of patients with chronic Chagas' heart disease,” says study collaborator and researcher at the INI's Chagas Disease Clinical Research Laboratory, Alejandro Hasslocher.
In addition to expanding the number of patients followed up and the follow-up time, the next stage of the research should investigate the increase in the selenium dose and the combination with another supplement, called coenzyme Q10, which can potentiate the effect of the therapy. “In recent years, studies have been published that indicate that the cardiovascular benefit of selenium supplementation may be greater with a dose of 200 micrograms, twice the amount we used in our clinical trial, and in association with coenzyme Q10. So, in the next phase of the research, we must update our protocol in search of the best results”, says Tania Araujo-Jorge.
The need for testing with a higher dose of the supplement is reinforced by the assessment of selenium levels in the blood of the patients who participated in the study. “At the end of the clinical trial, we observed an increase in the number of patients with ideal selenium levels in the group that received the supplementation. However, some still remained below this range, which indicates that the dose used may have been lower than necessary”, says the research collaborator and doctoral student of the Graduate Program in Cellular and Molecular Biology at the IOC, Beatriz Gonzaga.
The Selenium Project is the result of a long scientific effort in search of a therapy for a condition that causes high mortality, but remains neglected. According to the World Health Organization (WHO), between six and seven million people worldwide have chronic Chagas disease. In Brazil, the Ministry of Health points out that there are one to four million affected, and many cases are not even diagnosed.
Heart problems occur in about 30% of patients with chronic Chagas disease, affecting approximately 400 to 900 thousand people in Brazil alone. About 4,5 Brazilians die of Chagas disease each year, most of these deaths being caused by cardiac disorders such as arrhythmia, heart failure, thromboembolism and sudden death.
“Chronic Chagas heart disease, among all heart diseases, has the worst morbidity and mortality. When we compare clinical, hospitalization and death outcomes, Chagas heart disease has a worse prognosis. This is why it is necessary to look for new treatment strategies”, emphasizes infectologist Alejandro Hasslocher.
Two factors contribute to heart problems in Chagas disease. Causer of the aggravation, the parasite trypanosoma cruzi lodges in the heart and attacks the heart muscle. In an attempt to fight the parasite, the organism triggers an inflammatory reaction, which is not always well controlled and can be exaggerated, in order to further aggravate the damage to the organ. This process takes years and, as a result, the heart muscle is scarred, impairing its ability to pump blood and carry out the heart's electrical activity normally. Thus, about 30 years after infection, patients begin to show symptoms of Chagas heart disease, in general, with changes in the electrocardiogram, which are the first sign of the cardiac form of Chagas disease.

The options currently available for treatment are the same used by patients who have heart disease due to other causes, such as a heart attack. They are drugs that can improve heart function, but do not attack the causes of the problem itself, and cannot prevent Chagas heart disease from progressively getting worse.
“The treatments available for Chagas heart disease are extrapolated from other diseases, especially ischemic heart disease. However, Chagas disease has particularities because it is an inflammatory, progressive disease with the involvement of the immune system. A specific therapy, which interrupts these characteristics, can prevent symptoms and the worsening of the individual's health”, points out cardiologist Marcelo Holanda.
It was with this scenario in mind that researcher Tania Araujo-Jorge, a doctor who specializes in the study of the parasite T. cruzi and the biological mechanisms involved in Chagas disease, turned his attention to selenium. She considered that proteins that have this molecule in their composition, called selenoproteins, have an antioxidant action and, many times, can act in the modulation of inflammation. Therefore, in 1998, she started a line of research to investigate the role of selenium in Chagas disease.
The first results of this investigation were published in 2002. One article pointed out that patients with Chagas heart disease had low levels of selenium in their blood. Another study, carried out with mice, considered an experimental model, showed that selenium intake influenced mortality in the acute phase of the disease. In the following years, the researchers continued with their studies in mice, until they demonstrated that selenium could revert cardiac lesions in the chronic phase of experimental Chagas disease.
“The results of the experimental model studies impressed us a lot. For the first time, we saw an association between mortality in a parasitic disease and the animal's diet, with the only variation between groups being selenium. These studies were fundamental for us to be able to propose a therapy for the patients”, says Tania.
In 2009, the National Health Surveillance Agency (Anvisa) approved the request to carry out the clinical trial. However, the researchers had to overcome several challenges to carry out the research. First, there was no production of selenium capsules in Brazil. After some attempts, an agreement was signed with the company Catalent Brasil, which provided free selenium and placebo capsules for the project.
In addition, in 2005, there was a change in regulation: selenium, which was classified as a food supplement at the dose used in the clinical trial, was now considered a drug by Anvisa, which made the list of requirements that must be met longer. for conducting the clinical trial. In 2018, the substance was classified as a supplement again, but at that time, the study was already in the conclusion phase.
With the clinical trial protocol published in 2014, it took three years to complete patient recruitment. The monitoring of the last volunteer was completed in 2018, when the analysis of results began. The final stage of the work was also impacted by the Covid-19 pandemic, which generated a high demand for work for the professionals involved in the research.
The project coordinator points out that, since the first sample collection, in 2014, 30 researchers worked on the clinical trial, and are co-authors of the 2021 publication. Tania emphasizes the importance of public institutions in the search for solutions for neglected diseases.
“On the ClinicalTrials.gov platform [database for registering clinical trials], more than 68 studies related to cancer and more than 11 to HIV are registered. As for Chagas disease, there are only 65 studies, 28 of which in Brazil. This is what characterizes a neglected disease. The public network is at the forefront of research into Chagas in Brazil and around the world”, emphasizes the researcher.
led by IOC and INI, the Selenium Project clinical trial had a partnership with the State University of Rio de Janeiro (Uerj) and the Naval Academy. At the IOC, the Innovations in Therapies, Teaching and Bioproducts and Molecular Biology of Endemic Diseases laboratories worked on the research. The study was funded by the Oswaldo Cruz Foundation (F.iocruz), Ministry of Health, National Council for Scientific and Technological Development (CNPq), Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (Faperj) and Coordination for the Improvement of Higher Education Personnel (Capes).
Like other neglected infections, Chagas disease mostly affects poor people. the parasite trypanosoma cruzi it is transmitted by insects popularly known as kissing bugs, and settles in the body almost without causing symptoms. Without easy access to health services and the examination that could identify the infection, which still requires a medical request to be carried out, most carriers do not receive the diagnosis in the initial phase of the infection, when cure with antiparasitic treatment is more effective. .
Many live and die infected without knowing it, while others discover the disease decades after being infected, when complications appear, such as heart disease. In this phase, antiparasitic medication is still indicated, but it is less effective. In addition, medical evaluation is required for prescription in severe cases.
At the same time that it develops silently, Chagas disease is silenced, as carriers do not have the power or resources to make their problems and demands visible. Therefore, in addition to scientific results, the Selenium Project developed a social legacy.

In 2015, the researchers started an extension course aimed at people with Chagas disease with the theme 'We talk about Chagas with CienciArte'. Coordinated by the Laboratory of Innovations in Therapies, Teaching and Bioproducts, the course offered annual editions from 2015 to 2019, promoting practical workshops, in which participants were able to exchange experiences and reflect on the problem, not only as an infection caused by a parasite, but as a social, economic and cultural problem.
The initiative contributed to the founding of Associação Rio Chagas, in 2016, formed by carriers and affected by the disease, family members, friends and health professionals. At the request of the group, in 2019, the researchers developed an itinerant expedition, called 'Expresso Chagas 21', which took information about the disease and offered the opportunity for diagnosis in Minas Gerais cities historically affected by the disease.
“It was a very important trip. The disease only shows its face after 20, 30 years. So you have to do the exam, take the medication and, even if there is no cure, try to live longer. We felt like taking this to people”, says the president of the Rio Chagas Association, Josefa de Oliveira Silva, who recalls her own history with Chagas disease.
“When I was a child, in Pernambuco, we used to play with the barbers at home. They stung us, it itched, but in the fields, nobody knew what Chagas was. When I was 25 years old, in Campina Grande, the doctor said that my heart had grown a bit. It was only when my husband died and I came to live in Rio de Janeiro that I took the exam and found out that I had Chagas”, says Josefa, 68 years old, who has been undergoing treatment at the INI for 18 years.
With results published in 2021 in the scientific journal 'Plos Neglected Tropical Diseases', the 'Expresso Chagas 21' passed through four cities with a history of circulation of Chagas disease: Grão Mogol, Espinosa, Montes Claros and Lassance – where the scientist Carlos Chagas first described the condition, in 1901. expedition had a stop in the capital of Minas Gerais, Belo Horizonte.
Mounted in schools and universities, the project included workshops, games, laboratory activities and conversation circles set in scenarios characterized as train cars, in reference to the laboratory set up by Carlos Chagas on a train at the beginning of the last century. The activities received more than 2 visitors, including citizens and health professionals, of which 600 signed up to work in future health promotion activities and local associations of people with Chagas disease.
A survey showed that 80% of visitors were unaware of the possibility of treatment with antiparasitic medication. Among 1.110 participants who requested the diagnostic test, 222 had a positive result, which corresponds to 20%, in an active search process. Diagnosed people were referred for care at local health units through a partnership with municipal health departments.
Considering the context of Chagas disease, the authors of the study highlight the importance of 'Expresso Chagas 21' for both researchers and affected people. “It is fundamental to leave the laboratory and see that Chagas is much more than a disease. It is a problem with several dimensions, including biomedical, epidemiological, political-economic and social.iocculture”, points out Tania Araujo-Jorge.
“The total development time for a new medicine is long and only at the end of this process will the research actually reach the population. Thus, it is extremely important to narrow the distance between academia and society. For the researcher, this experience makes it possible to humanize the research. For the participant, it is a possibility of empowerment and of demystifying science”, emphasizes the post-doctoral fellow of the IOC, Roberto Ferreira, collaborator of the Selênio Project and one of the coordinators of 'Expresso Chagas 21'.
Celebrated this Sunday, January 30, the World Day for Neglected Tropical Diseases draws attention to infections that affect more than 1 billion people in the world, but receive little attention and investment. Affecting mainly poor people, diseases such as Chagas disease, dengue, leishmaniasis, leprosy, schistosomiasis and verminoses cause great damage to health, can lead to death and even worsen people's living conditions, as they make it difficult to stay in school and in the job market. work.
Among the many faces of negligence, which includes lack of access to available prevention, diagnosis and treatment measures, is the low investment in research and development of safe and effective therapies. It is in this context that the 'Selenium Project', led by the Oswaldo Cruz Institute (IOC/Fiocruz) in partnership with the Evandro Chagas National Institute of Infectology (INI/Fiocruz), celebrates another step in the search for a new therapy for heart problems caused by chronic Chagas disease.

Published in the international scientific journal 'EClinicalMedicine', the result of the first clinical trial with selenium supplementation for patients with Chagas heart disease pointed out a potential benefit of the treatment, in at least a subgroup of patients. The study included patients with chronic Chagas disease with mild to moderate heart problems, which are classified as stage B. The work confirmed the safety of using selenium, with no record of adverse reactions. In the subgroup of patients with moderate heart disease, classified as stage B2, the analyzes showed that the evolution of the severity of the problems improved after treatment.
According to the authors of the research, the result is positive and indicates that further studies should be carried out. “We generated the first evidence, obtained in a randomized clinical trial, on the benefit of selenium for patients in stage B2 of chronic heart disease in Chagas disease. It was a statistically significant result, but in a small sample. Now, confirmation in new research is important, including longer follow-up time, more patients in stage B2, patients in stage C and volunteers from different regions of Brazil”, says the project coordinator, researcher at the Laboratory of Innovations in Therapy, Education and Bioproducts and director of IOC, Tania Cremonini de Araujo-Jorge.
“This was the first randomized clinical trial that tested the use of selenium to prevent worsening of the contractile function of the heart in Chagas heart disease. The trial showed that there is a subgroup of patients in whom the treatment was beneficial, which encouraged us a lot and raised questions for further research”, adds the first author of the article, a cardiologist and researcher at the Laboratory of Clinical Research in Chagas Disease at the INI , Marcelo Holland.
Sixty-six patients treated at the INI's Chagas disease outpatient clinic participated in the survey. To assess the effect of therapy, volunteers were divided into two groups. One received daily supplementation with selenium capsules and the other, considered as a control, received identical capsules containing an inert compound, called a placebo. Each patient was followed up for one year, with clinical consultations, laboratory tests and heart tests.
The research followed protocols considered the gold standard for clinical trials. The volunteers were randomly allocated to the groups to receive the treatment or the placebo, through a procedure called randomization, which causes the two groups to have patients with similar profiles in terms of factors that may influence the outcome of the study, such as age, gender, severity of heart problems, and medications used for heart disease.
Furthermore, during the entire follow-up, both patients and raters were unaware of who was receiving selenium and who was taking a placebo. Called blinding, the procedure avoids the predisposition to recognize signs of improvement in those who used the medication or worsening in those who did not.
At the end of the study, the evolution of the disease in the two groups was compared. The most relevant result was observed among patients with stage B2 heart disease, who initially had a moderate loss of heart contraction strength. After a year of follow-up, the volunteers who took selenium maintained or improved their heart function, while those who took a placebo maintained the same condition or worsened. Considering the average of each group, the difference was statistically significant.
Among patients with stage B1 heart disease, who had mild changes in cardiac function at the beginning of the study, no statistically significant difference was observed between the treated group and the placebo group after one year of follow-up. However, some data indicate that there may be benefit from treatment, and that longer follow-up would be indicated, as some cases of improvement in heart function were observed only among patients who took selenium. In total participants, on average, disease progression was somewhat less pronounced among selenium-treated volunteers.

According to the authors of the study, a longer follow-up of the volunteers should contribute to elucidate the potential benefit of selenium. “Based on the results of the clinical trial, we can indicate that selenium replacement could be an adjuvant treatment to delay the progression of the disease. Now, it is necessary to increase the follow-up period from one to five years and verify whether this positive trend of less progress is maintained. If that happens, the next step is to incorporate selenium supplementation into the treatment routine of patients with chronic Chagas' heart disease,” says study collaborator and researcher at the INI's Chagas Disease Clinical Research Laboratory, Alejandro Hasslocher.
In addition to expanding the number of patients followed up and the follow-up time, the next stage of the research should investigate the increase in the selenium dose and the combination with another supplement, called coenzyme Q10, which can potentiate the effect of the therapy. “In recent years, studies have been published that indicate that the cardiovascular benefit of selenium supplementation may be greater with a dose of 200 micrograms, twice the amount we used in our clinical trial, and in association with coenzyme Q10. So, in the next phase of the research, we must update our protocol in search of the best results”, says Tania Araujo-Jorge.
The need for testing with a higher dose of the supplement is reinforced by the assessment of selenium levels in the blood of the patients who participated in the study. “At the end of the clinical trial, we observed an increase in the number of patients with ideal selenium levels in the group that received the supplementation. However, some still remained below this range, which indicates that the dose used may have been lower than necessary”, says the research collaborator and doctoral student of the Graduate Program in Cellular and Molecular Biology at the IOC, Beatriz Gonzaga.
The Selenium Project is the result of a long scientific effort in search of a therapy for a condition that causes high mortality, but remains neglected. According to the World Health Organization (WHO), between six and seven million people worldwide have chronic Chagas disease. In Brazil, the Ministry of Health points out that there are one to four million affected, and many cases are not even diagnosed.
Heart problems occur in about 30% of patients with chronic Chagas disease, affecting approximately 400 to 900 thousand people in Brazil alone. About 4,5 Brazilians die of Chagas disease each year, most of these deaths being caused by cardiac disorders such as arrhythmia, heart failure, thromboembolism and sudden death.
“Chronic Chagas heart disease, among all heart diseases, has the worst morbidity and mortality. When we compare clinical, hospitalization and death outcomes, Chagas heart disease has a worse prognosis. This is why it is necessary to look for new treatment strategies”, emphasizes infectologist Alejandro Hasslocher.
Two factors contribute to heart problems in Chagas disease. Causer of the aggravation, the parasite trypanosoma cruzi lodges in the heart and attacks the heart muscle. In an attempt to fight the parasite, the organism triggers an inflammatory reaction, which is not always well controlled and can be exaggerated, in order to further aggravate the damage to the organ. This process takes years and, as a result, the heart muscle is scarred, impairing its ability to pump blood and carry out the heart's electrical activity normally. Thus, about 30 years after infection, patients begin to show symptoms of Chagas heart disease, in general, with changes in the electrocardiogram, which are the first sign of the cardiac form of Chagas disease.

The options currently available for treatment are the same used by patients who have heart disease due to other causes, such as a heart attack. They are drugs that can improve heart function, but do not attack the causes of the problem itself, and cannot prevent Chagas heart disease from progressively getting worse.
“The treatments available for Chagas heart disease are extrapolated from other diseases, especially ischemic heart disease. However, Chagas disease has particularities because it is an inflammatory, progressive disease with the involvement of the immune system. A specific therapy, which interrupts these characteristics, can prevent symptoms and the worsening of the individual's health”, points out cardiologist Marcelo Holanda.
It was with this scenario in mind that researcher Tania Araujo-Jorge, a doctor who specializes in the study of the parasite T. cruzi and the biological mechanisms involved in Chagas disease, turned his attention to selenium. She considered that proteins that have this molecule in their composition, called selenoproteins, have an antioxidant action and, many times, can act in the modulation of inflammation. Therefore, in 1998, she started a line of research to investigate the role of selenium in Chagas disease.
The first results of this investigation were published in 2002. One article pointed out that patients with Chagas heart disease had low levels of selenium in their blood. Another study, carried out with mice, considered an experimental model, showed that selenium intake influenced mortality in the acute phase of the disease. In the following years, the researchers continued with their studies in mice, until they demonstrated that selenium could revert cardiac lesions in the chronic phase of experimental Chagas disease.
“The results of the experimental model studies impressed us a lot. For the first time, we saw an association between mortality in a parasitic disease and the animal's diet, with the only variation between groups being selenium. These studies were fundamental for us to be able to propose a therapy for the patients”, says Tania.
In 2009, the National Health Surveillance Agency (Anvisa) approved the request to carry out the clinical trial. However, the researchers had to overcome several challenges to carry out the research. First, there was no production of selenium capsules in Brazil. After some attempts, an agreement was signed with the company Catalent Brasil, which provided free selenium and placebo capsules for the project.
In addition, in 2005, there was a change in regulation: selenium, which was classified as a food supplement at the dose used in the clinical trial, was now considered a drug by Anvisa, which made the list of requirements that must be met longer. for conducting the clinical trial. In 2018, the substance was classified as a supplement again, but at that time, the study was already in the conclusion phase.
With the clinical trial protocol published in 2014, it took three years to complete patient recruitment. The monitoring of the last volunteer was completed in 2018, when the analysis of results began. The final stage of the work was also impacted by the Covid-19 pandemic, which generated a high demand for work for the professionals involved in the research.
The project coordinator points out that, since the first sample collection, in 2014, 30 researchers worked on the clinical trial, and are co-authors of the 2021 publication. Tania emphasizes the importance of public institutions in the search for solutions for neglected diseases.
“On the ClinicalTrials.gov platform [database for registering clinical trials], more than 68 studies related to cancer and more than 11 to HIV are registered. As for Chagas disease, there are only 65 studies, 28 of which in Brazil. This is what characterizes a neglected disease. The public network is at the forefront of research into Chagas in Brazil and around the world”, emphasizes the researcher.
led by IOC and INI, the Selenium Project clinical trial had a partnership with the State University of Rio de Janeiro (Uerj) and the Naval Academy. At the IOC, the Innovations in Therapies, Teaching and Bioproducts and Molecular Biology of Endemic Diseases laboratories worked on the research. The study was funded by the Oswaldo Cruz Foundation (F.iocruz), Ministry of Health, National Council for Scientific and Technological Development (CNPq), Carlos Chagas Filho Foundation for Research Support in the State of Rio de Janeiro (Faperj) and Coordination for the Improvement of Higher Education Personnel (Capes).
Like other neglected infections, Chagas disease mostly affects poor people. the parasite trypanosoma cruzi it is transmitted by insects popularly known as kissing bugs, and settles in the body almost without causing symptoms. Without easy access to health services and the examination that could identify the infection, which still requires a medical request to be carried out, most carriers do not receive the diagnosis in the initial phase of the infection, when cure with antiparasitic treatment is more effective. .
Many live and die infected without knowing it, while others discover the disease decades after being infected, when complications appear, such as heart disease. In this phase, antiparasitic medication is still indicated, but it is less effective. In addition, medical evaluation is required for prescription in severe cases.
At the same time that it develops silently, Chagas disease is silenced, as carriers do not have the power or resources to make their problems and demands visible. Therefore, in addition to scientific results, the Selenium Project developed a social legacy.

In 2015, the researchers started an extension course aimed at people with Chagas disease with the theme 'We talk about Chagas with CienciArte'. Coordinated by the Laboratory of Innovations in Therapies, Teaching and Bioproducts, the course offered annual editions from 2015 to 2019, promoting practical workshops, in which participants were able to exchange experiences and reflect on the problem, not only as an infection caused by a parasite, but as a social, economic and cultural problem.
The initiative contributed to the founding of Associação Rio Chagas, in 2016, formed by carriers and affected by the disease, family members, friends and health professionals. At the request of the group, in 2019, the researchers developed an itinerant expedition, called 'Expresso Chagas 21', which took information about the disease and offered the opportunity for diagnosis in Minas Gerais cities historically affected by the disease.
“It was a very important trip. The disease only shows its face after 20, 30 years. So you have to do the exam, take the medication and, even if there is no cure, try to live longer. We felt like taking this to people”, says the president of the Rio Chagas Association, Josefa de Oliveira Silva, who recalls her own history with Chagas disease.
“When I was a child, in Pernambuco, we used to play with the barbers at home. They stung us, it itched, but in the fields, nobody knew what Chagas was. When I was 25 years old, in Campina Grande, the doctor said that my heart had grown a bit. It was only when my husband died and I came to live in Rio de Janeiro that I took the exam and found out that I had Chagas”, says Josefa, 68 years old, who has been undergoing treatment at the INI for 18 years.
With results published in 2021 in the scientific journal 'Plos Neglected Tropical Diseases', the 'Expresso Chagas 21' passed through four cities with a history of circulation of Chagas disease: Grão Mogol, Espinosa, Montes Claros and Lassance – where the scientist Carlos Chagas first described the condition, in 1901. expedition had a stop in the capital of Minas Gerais, Belo Horizonte.
Mounted in schools and universities, the project included workshops, games, laboratory activities and conversation circles set in scenarios characterized as train cars, in reference to the laboratory set up by Carlos Chagas on a train at the beginning of the last century. The activities received more than 2 visitors, including citizens and health professionals, of which 600 signed up to work in future health promotion activities and local associations of people with Chagas disease.
A survey showed that 80% of visitors were unaware of the possibility of treatment with antiparasitic medication. Among 1.110 participants who requested the diagnostic test, 222 had a positive result, which corresponds to 20%, in an active search process. Diagnosed people were referred for care at local health units through a partnership with municipal health departments.
Considering the context of Chagas disease, the authors of the study highlight the importance of 'Expresso Chagas 21' for both researchers and affected people. “It is fundamental to leave the laboratory and see that Chagas is much more than a disease. It is a problem with several dimensions, including biomedical, epidemiological, political-economic and social.iocculture”, points out Tania Araujo-Jorge.
“The total development time for a new medicine is long and only at the end of this process will the research actually reach the population. Thus, it is extremely important to narrow the distance between academia and society. For the researcher, this experience makes it possible to humanize the research. For the participant, it is a possibility of empowerment and of demystifying science”, emphasizes the post-doctoral fellow of the IOC, Roberto Ferreira, collaborator of the Selênio Project and one of the coordinators of 'Expresso Chagas 21'.
The non-profit reproduction of the text is allowed as long as the source is cited (Comunicação / Instituto Oswaldo Cruz)